[exclusive] list of global rheumatic treatment drugs in 2022

Rheumatoid arthritis (RA) is a chronic, progressive, multiple, invasive autoimmune disease, with synovitis and extraarticular lesions as the main clinical manifestations There was no significant regional and age difference, but there were obvious family genetic characteristics In recent years, the incidence rate of rheumatic diseases has increased significantly and the mortality rate is higher Clinical research has found that about 30% of the world's people suffer from rheumatic diseases of different degrees, and the standard mortality rate is 1.28% - 2.98% The complications can lead to poor joint function, seriously affect the quality of life of patients, and bring heavy economic burden to the society Therefore, the effective treatment of RA has become the focus of the global pharmaceutical industry According to the evaluation Pharma report, RA treatment drugs rank second in the global drug market, second only to anti-tumor drugs (sales of US $93.7 billion in 2016) In 2016, the global sales of anti rheumatic drugs reached US $53.3 billion, an increase of nearly US $4.5 billion compared with us $48.8 billion in 2015 According to the report of evaluate Pharma, the global sales of anti rheumatic drugs will reach 54.5 billion US dollars in 2022 1、 In 2016-2022, the top 10 selling anti wind and humidity medicine of the sales enterprise at present is xiumeile, which has a global sales volume of more than 16 billion US dollars in 2016, accounting for 30.2% of the market share According to the report of evaluate Pharma, it will still occupy the first place in the market in 2022 Because of the popularity of otezla, celegen also maintains a leading position; otezla's sales in 2016 exceeded $1 billion, and according to the evaluation Pharma report, its global sales will reach $3.673 billion in 2022, with a CAGR of 24% Top 10 sales enterprises in 2016-2022, top 5 global RA treatment drugs sales in 2022 according to the forecast of evaluation Pharma report, the top five global anti rheumatic drugs in 2022 are: Top 1 In 2022, the global sales volume of adamuumab Humira is US $15.901 billion, with a compound growth rate of - 1%; in 2022, the global sales volume of top 2 ibrel is US $5.276 billion, with a compound growth rate of - 9%; in 2022, the global sales volume of top 3 aptizla is US $3.673 billion, with a compound growth rate of + 24%; in 2022, the global sales volume of top 4 gelimuab simponi is US $3.582 billion, with a compound growth rate of + 24%; in 2022, with a compound growth rate of The overall growth rate is + 6%; the global sales of the top 5 infliximab REMICADE in 2022 is US $2.742 billion, with a compound growth rate of - 16% In 2022, the global sales of RA treatment drugs top 51 Humira [English trade name] Humira [Chinese trade name] sumil [Chinese trade name] adamutumab [dosage form and specification] injection, 40mg / 0.8ml [manufacturer name] abbvie / Eisai Humira was approved by the U.S Food and Drug Administration (FDA) on December 31, 2002 The approved dosage form is injection, with the specification of 40mg / 0.8ml It is a fully humanized monoclonal antibody with high-efficiency and specific combination with TNF, which can be used to treat RA, psoriatic arthritis and ankylosing spondylitis (as), and also can effectively treat inflammatory bowel disease Humira has been approved by the State Food and Drug Administration (CFDA) for 2 indications for the treatment of RA and as Global sales of abbvie in recent three years: from the sales data, we can see that abbvie has been the world's top seller in recent three years, and the sales are growing As its patent will expire in 2018, the sales volume may be impacted by generic drugs, and the compound growth rate will be reduced According to the report of evaluate Pharma, the sales volume in 2022 will be USD 15.901 billion Domestic market sales of adamumumab in recent seven years: from PDB database, it can be seen that adamumumab has grown rapidly since it was listed in China in 2010 In 2013, the peak sales volume was reached, and the sales volume of sample hospitals reached 24.6 million yuan After 2013, the sales volume of domestic market declined slightly, and the sales volume of sample hospitals decreased to 19.44 million yuan in 2016 2 Enbrel [English trade name] Enbrel [Chinese trade name] enli [Chinese drug name] etanercept [dosage form and specification] injection, 25mg / vial & 50mg / ml [manufacturer name] Amgen / Pfizer / Takeda Enbrel was approved by FDA on November 2, 1998 The approved dosage forms are injection with specifications of 25mg / vial and 50mg / ml it is used for the treatment of biological DMARD (anti rheumatic and anti rheumatic drugs for improving the condition) of RA and as At present, etanercept has been approved by CFDA for the treatment of moderate to severe active RA and severe active as in adult patients Global sales of Amgen & Pfizer in recent three years: according to the sales data, the global sales of Amgen & Pfizer in recent three years are relatively stable According to the report of evaluate Pharma, the sales will fall sharply in 2022, with a compound growth rate of - 9%, which may be related to the impact of generic drugs Sales in the domestic market of enacep in the past seven years: from the PDB database, it can be seen that the sales of enacep reached the peak in the domestic market in 2013, and the sales of sample hospitals reached 28.24 million yuan After 2013, the sales fell slightly In 2016, the sales volume of sample hospitals was 2015 million yuan, which was slightly better than that of biadamumab 3 Otezla [English trade name] otezla [Chinese drug name] tablet, 10 mg / 20 mg / 30 mg [manufacturer name] celegen otezla was approved by FDA on March 21, 2014 The approved dosage form is tablet, the specification is 10 mg, 20 mg and 30 mg The drug is an oral, selective phosphodiesterase 4 (PDE 4) Inhibitor, used to treat adult patients with moderate to severe plaque psoriasis, is the first and only drug approved by FDA for plaque type rheumatoid arthritis At present, the drug has not entered the Chinese market Global sales of celegen in recent three years: the sales volume of otezla in the second year of listing reached 472 million US dollars, the global sales volume reached 1.017 billion US dollars in 2016, with an annual growth rate of 115% According to the report of evaluate Pharma, the sales volume will exceed 3 billion US dollars in 2022 4 Simponi [English trade name] simponi [Chinese drug name] golimub [dosage form and specification] injection, 50mg / vial [manufacturer name] Johnson & Johnson / Merck Simponi was approved by FDA on April 24, 2009 The approved dosage form is injection, with the specification of 50mg / vial Golimub is an all human monoclonal antibody injected subcutaneously once a month, which is used to treat moderate to severe RA, psoriatic arthritis and active as On July 18, 2013, FDA approved the use of simponi aria for intravenous injection in the treatment of moderate to severe RA At present, the drug has not entered the Chinese market Global sales of glymumab (Johnson & Merck) in recent three years: 5 REMICADE [English trade name] REMICADE [Chinese drug name] infliximab [Chinese trade name] Leke [dosage form and specification] injection, 100mg / vial [manufacturer name] Johnson / MSD / MITSUBISHI REMICADE was approved by FDA on August 24, 1998 The approved dosage form is injection, with the specification of 100mg / vial It is used to treat RA, moderate and severe active Crohn's disease, fistula Crohn's disease and biological products of as The global sales of infliximab (Johnson & MSD) in the past three years: the sales of infliximab (Johnson & MSD) has declined in the past three years, which may be related to the approval and marketing of the biological similar drug infrared (infliximab - dyyb) injection developed by Pfizer in the United States Clinical data show that infliximab - dyyb and REMICADE have therapeutic equivalence Sales of infliximab in the domestic market in the past seven years: Infliximab was approved to be imported by CFDA in 2006, which was earlier than the similar drugs adalimumab and etanercept According to the PDB database, the domestic sales of infliximab in the past seven years have been increasing In 2016, the sales of sample hospitals reached 121 million yuan, about 6 times of the sales of adalimumab and etanercept 3、 According to the report of evaluate Pharma, the five most potential drugs under development in 2022 are abt-494 of Alberta, sirukumab of Johnson & Johnson, zilretta of flexion, abp-710 of Amgen and filgotinib of Gilead and Galapagos, accounting for about 6% of the market share of RA drugs Top 5 potential therapeutic drugs for RA in 2022: 1 Https:// Https://igeahub.com/3 Http:// 4 Https:// Https:// Http:// Http:// Http://pdb.pharmadl.com/